EPO approves BioPorto’s NGAL Cutoff patent for issue

Hellerup, DENMARK

Today, the European Patent Office (EPO) has announced, that BioPorto's NGAL Cutoff patent has been approved for issue.

BioPorto’s NGAL patent portfolio now comprises, besides the above-mentioned patent, BioPorto’s issued NGAL ratio patent, NGAL forms patent and NGAL trauma patent. BioPorto’s European NGAL exclusion patent was ruled invalid earlier this year, and BioPorto has appealed this decision. The company estimates that the portfolio of patents provides a sufficient coverage of the NGAL area. Please see BioPorto’s Annual Report for a description of BioPorto’s issued patents, applications and oppositions.

Peter Mørch Eriksen, CEO of BioPorto, comments: "We are very pleased that the cutoff patent is now approved for issue. Along with the other patents in our IP portfolio it ensures our coverage and maintain our position as a major player in the NGAL market.”

Further details from:

Peter Mørch Eriksen, CEO

Phone 45 29 00 00, mail investor@bioporto.com


The kidney biomarker NGAL

Every year about 13 million people are struck by acute kidney injury worldwide, of whom about 4 million die. Nevertheless, there has been no real progress in methods of diagnosing kidney injury over the last half century. Existing methods, such as serum creatinine determination, only signal kidney failure 24-72 hours after the injury has taken place. In contrast, NGAL rises to diagnostic levels within a few hours of kidney injury and thus enables the physician to make vital clinical decisions before the damage progresses to potentially fatal renal shutdown. In addition to helping the patient, cost-benefit analyses show that implementing NGAL testing will contribute to reducing hospital costs in the management of kidney injury and its consequences.


About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.


20 announcement 2016 11 08.pdf